Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Dr.reddy

    Jump to

    • Dr Reddy’s: Is the weight loss drug the next big opportunity?

      The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow

    • Adani Infra, Tata Power, Dr.Reddy, JSW Steel in Focus

      Adani Infra to acquire 30% stake in PSP projects. Tata Power partners with Bhutan's Druk Green Power Corporation to develop 5,000 MW of clean energy projeects in Bhutan. Watch here for my details

    • Why should one avoid fresh bets on Dr Reddy’s?

      The Revlimid opportunity is transitional and its contribution to profitability is likely to reduce from CY27

    • Dr Reddy's Laboratories incorporates wholly-owned subsidiary in Jamaica; stock rises 1%

      Dr Reddy’s stock has given a return of 18.88 percent over the last six months. The benchmark Nifty50 index has given a return of 14.30 percent over the same duration.

    • Who makes a better suitor for Cipla and what is in it for shareholders?

      Torrent Pharma and Dr Reddy’s are among the bidders. The combined India business can surpass Sun Pharma’s from any of these two deals. Investors in both Dr Reddy’s and Cipla should wait for clarity to emerge

    • Another great quarter for Dr Reddy’s, but is it sustainable?

    • Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug

    • Cash Trade | Dr Reddy's bouncing off channel support

    • Markets extend rally to 3rd day; Sensex climbs over 300 points

    • Dr Reddy’s: Acceleration in EM opportunity to help re-rate company

    • Dr Reddy’s: Improving exposure to EMs adds to investment case

    • COVID-19 vaccine | India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light

    • Deregulation of vaccine rollout: What it means for pharma players

    • Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

    • COVID Vaccine: The opportunities for investors - Part I

    • Cadila: a formidable play in Covid times and beyond

    • Ideas For Profit | Dr Reddy’s: An opportunity for risk takers

    • Dr Reddy's to recall 1,752 bottles of heartburn drug in the US

    • Dr Reddy's launches generic lipid-regulating tablets in US

    • Rising stars? 14 stocks reported over 100% surge in PAT

    • Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations

    • Dr Reddy’s Labs falls 4% as US FDA issues 11 observations to Bachupally plant

    • Upbeat CLSA view, procedural observations from US FDA send DRL stock up 3%

    • Dr Reddy’s tanks 6% on dismal Q1; brokerages turn cautious on stock

    • Dr Reddy’s US FDA developments get a thumbs up from brokerages

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347